Specialties

Oncology

Emergencies, staging and treatment toxicity

The Oncology engine supports the doctors who see people with cancer when something goes wrong: acute physicians, emergency teams and residents on the oncology ward. It recognises the oncological emergencies first, grades chemotherapy and immunotherapy toxicity, summarises staging and the evidence-based options for discussion, and leaves decisions about anticancer treatment with the treating team and the multidisciplinary meeting.

Who it is for

  • Acute and emergency physicians assessing a patient on chemotherapy, targeted therapy or immunotherapy who has become unwell
  • Oncology and haematology residents managing toxicity, supportive care and emergencies out of hours
  • Physicians preparing a new or suspected cancer for the multidisciplinary meeting who want staging, markers and options laid out

What it does

  • Emergencies first

    Treats neutropenic sepsis on suspicion without waiting for the count and stratifies it with MASCC, and recognises metastatic cord compression, superior vena cava obstruction, hypercalcaemia, hyperviscosity, raised intracranial pressure and malignant bowel obstruction.

  • Tumour lysis by risk

    Assesses tumour lysis syndrome by the Cairo-Bishop definitions, matches prophylaxis to tumour type and burden, and sets out monitoring of potassium, phosphate, calcium, urate and renal function.

  • Immunotherapy toxicity graded

    Considers any new symptom on a checkpoint inhibitor possibly immune-related, grades it by CTCAE, and manages by grade: continue or hold treatment, start steroids, and escalate when there is no response.

  • Staging and options for discussion

    Gives the applicable staging system, ECOG performance status and the histological and molecular markers that change treatment, then the treatment intent and standard options by line, with expected benefit in absolute terms.

  • Questions for the Multidisciplinary Team

    When treatment selection is at issue, adds a section listing what the multidisciplinary meeting will need to decide and the tests it will want, so the case arrives ready for discussion.

  • Supportive care alongside treatment

    Covers antiemetics by emetogenic risk, pain by mechanism, venous thromboembolism risk with the Khorana score, bone health and nutrition, and raises early palliative care and advance care planning alongside active treatment.

How it works

  1. The clinician gives the tumour type, stage, histology and biomarkers, the treatment received with the date of the last cycle, performance status and the new problem.
  2. The engine checks first for an oncological emergency or severe toxicity and lists the immediate actions.
  3. It grades the problem with the named system, such as MASCC, CTCAE or Cairo-Bishop, and looks for a reversible cause rather than blaming the cancer by default.
  4. It sets out management and supportive care, flags interactions with oral anticancer drugs and, where treatment choice is the question, lists the options and the questions for the multidisciplinary meeting.
  5. The report closes with the information still needed and references read from PubMed, ClinicalTrials.gov and, for named drugs, DailyMed.

What to include

  • Tumour type, stage, histology and biomarkers
  • Treatment received, with the date of the last cycle
  • Performance status and the new problem
  • Blood count, calcium, renal and liver function, imaging

Example cases

  • Day 9 after R-CHOP, temperature 38.6, neutrophils 0.2, BP 96/58. Immediate management and risk stratification?
  • Metastatic melanoma on ipilimumab and nivolumab, 8 loose stools a day with blood for 3 days. Grading and treatment?
  • Known prostate cancer with 2 days of back pain, leg weakness and urinary retention. Urgent plan?

What the report contains

  1. Immediate Safety Actions, when a red flag is present
  2. Conclusion and Recommendation
  3. Clinical Dashboard
  4. Differential Diagnosis
  5. Recommended Work-up, with toxicity grading and staging where relevant
  6. Management Plan, including supportive care
  7. Questions for the Multidisciplinary Team, when treatment selection is at issue
  8. Information Needed
  9. Key Evidence and References

Limits

  • Decisions about systemic anticancer treatment belong to the treating oncology team and the multidisciplinary meeting. The engine sets out options and evidence; it does not choose a regimen for a patient.
  • It knows only the cancer history entered. Instructions from the treating unit, such as dose holds and toxicity pathways for a trial drug, take precedence and should be confirmed with that unit.
  • Drug labels attached to answers are US labels, and access to anticancer drugs, growth factors and biomarker testing varies between countries and hospitals.

Frequently asked questions

How is the MASCC score used in febrile neutropenia?

The MASCC risk index weighs the burden of illness, hypotension, chronic lung disease, tumour type and previous fungal infection, dehydration, outpatient status and age. A score of 21 or more identifies adults at low risk of complications who may be considered for oral or outpatient treatment under local protocols. It is applied after the first antibiotic dose, never instead of it.

Should steroids be started before the MRI in suspected spinal cord compression?

In suspected metastatic cord compression with neurological symptoms or signs, guidelines generally advise starting dexamethasone at once rather than waiting for imaging, except where lymphoma is a likely cause and a tissue diagnosis may be needed first. MRI of the whole spine is arranged urgently, and the oncology and spinal surgical teams are contacted the same day.

How are immune checkpoint inhibitor side effects graded?

By CTCAE grade, from 1 (mild) to 5 (death). Management follows the grade: grade 1 usually continues treatment with monitoring, grade 2 holds it and often starts steroids, and grades 3 and 4 need high-dose steroids, admission and specialist input, with further immunosuppression if there is no response. Treating-unit protocols take precedence.

Can it decide which chemotherapy a patient should have?

No. It summarises staging, performance status, markers, treatment intent and the standard options with their expected absolute benefit and main toxicities, and lists the questions the multidisciplinary meeting needs to answer. Choosing and prescribing anticancer treatment stays with the treating team.